Recent 8-K filings for IOBTQ
Highest-materiality recent filing
IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated
- Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.
- Chapter 7 trustee to liquidate assets; it is unlikely common stockholders will receive any payment.
-
IO Biotech files Chapter 7 bankruptcy, ceases operations, all directors and employees terminated
Filed Chapter 7 bankruptcy petition in Delaware on March 31, 2026; company ceases operations.
-
IO Biotech receives Nasdaq MVLS deficiency notice; 180 days to comply
Notice received Feb 12, 2026; MVLS below $50M for 30 consecutive business days.
-
IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James
Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.
-
IO Biotech to explore strategic alternatives including merger, sale, or liquidation
Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.
-
IO Biotech receives Nasdaq bid price deficiency notice; has until June 16, 2026 to regain compliance
Nasdaq notified IO Biotech on Dec 17, 2025 that bid price < $1.00 for 30 consecutive days.
-
IO Biotech chief accounting officer Burkavage resigns; CFO Sullivan to succeed
Brian Burkavage resigns as SVP and Chief Accounting Officer effective December 12, 2025 to pursue another opportunity; no dispute with company.
-
IO Biotech updates investor deck for Jefferies conference; no specific new data in exhibit
Company will present at Jefferies Global Healthcare Conference on November 18, 2025.
-
IO Biotech Q3: Phase 3 melanoma trial narrowly misses PFS endpoint; cash $30.7M, runway to Q1 2026
Phase 3 IOB-013 trial in advanced melanoma showed PFS improvement but narrowly missed statistical significance; FDA meeting in December for new registrational trial design.
-
FDA advises IO Biotech not to submit BLA for Cylembio; workforce cut by ~50%
FDA recommends against BLA submission based on IOB-013 trial data (PFS improved but missed statistical significance).
-
IO Biotech Q2 net loss $26.2M; Ph3 Cylembio trial misses PFS endpoint, plans FDA meeting fall 2025
Phase 3 trial of Cylembio+Keytruda in advanced melanoma showed clinical improvement in PFS but narrowly missed statistical significance.
-
IO Biotech Phase 3 Cylembio trial misses statistical significance; PFS improved 19.4 vs 11.0 mo
Primary endpoint PFS HR=0.77 (CI 0.58-1.00), p=0.056, missed significance threshold p≤0.045.
-
IO Biotech draws €12.5M Tranche B from EIB, issues warrant for 4.22M shares at $1.3159
Satisfied conditions to draw €12.5M second tranche (Tranche B) from EIB loan facility of up to €57.5M.
-
IO Biotech enters CEO severance agreement providing 12-18 months pay and equity vesting
Severance pay: 12 months base salary on qualifying termination; 18 months if termination within 6 months pre- or 12 months post-Change in Control.
-
IO Biotech stockholders elect David Smith to board, ratify EY as auditor
David Smith elected as Class I director with 40,444,898 votes for, 3,010,542 withheld, 8,622,498 broker non-votes.
-
IO Biotech regains Nasdaq minimum bid price compliance after deficiency notice
Received December 26, 2024 notice from Nasdaq for bid price below $1.00 for 30 consecutive days.
-
IO Biotech Q1 net loss $22.4M; Phase 3 melanoma vaccine readout on track for Q3 2025
Net loss of $22.4M in Q1 2025 vs $19.5M in Q1 2024; R&D expenses rose to $16.4M.
-
IO Biotech issues warrant to EIB for up to 5.6M shares at $0.8891; €10M draw expected May 6
Issued Tranche A Warrant to EIB to purchase up to 5,623,664 shares of common stock at $0.8891 per share.
-
IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026
Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.72 · Most common event other_material